



Kala Pharmaceuticals to Present at 5th Annual Ophthalmology Innovation Summit @ AAO

Waltham, Mass., November 6, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Guillaume Pfefer, Ph.D., Kala's President and Chief Executive Officer, is scheduled to present at the 5th Annual Ophthalmology Innovation Summit @ AAO being held November 14, 2013 at the Sheraton New Orleans in New Orleans, LA. Dr. Pfefer's presentation will take place on Thursday, November 14, 2013 at 11:26 a.m.

About The Ophthalmology Innovation Summit @ AAO

The Ophthalmology Innovation Summit @ AAO was developed to foster innovation and facilitate business transactions amongst a diverse group of key players in the ophthalmic field. The goal of the conference is to provide a forum for addressing key issues impacting the ophthalmic field and a platform to showcase the most promising private ophthalmic companies. <http://www.ophthalmologysummit.com/aa/>

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant unmet needs in both front and back of the eye based on the Company's proprietary Mucus Penetrating Particle (MPP) technology. Kala's topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Kala's product development pipeline includes: a 1% formulation of loteprednol etabonate (1% LE-MPP) to treat post-surgical ocular inflammation and pain, expected to enter a pivotal clinical study in 2014; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, expected to enter clinical trials in 2014, and a topically applied receptor tyrosine kinase inhibitor (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD), which is advancing toward selection of a clinical candidate in 2014.

Kala's approach to penetrating mucus layers also has potential application in other disease areas, such as respiratory, female reproductive tract, and gastrointestinal diseases, and in these areas the Company will seek partners to out-license its breakthrough technology. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, maintains an esteemed group of advisors including co-founder and MIT professor Dr. Robert Langer, and is backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Crown Venture Fund, LLC. For more information, please visit www.kalarx.com.

Contact:

Kala Pharmaceuticals, Inc.

Tel: 781 810 4748

info@kalarx.com

Media:

Gina Nugent

The Yates Network

gina@theyatesnetwork.com